<DOC>
	<DOCNO>NCT00836225</DOCNO>
	<brief_summary>The primary purpose trial ass safety tolerability ISIS-SGLT2Rx give increase single dos assess safety tolerability dose give multiple time .</brief_summary>
	<brief_title>Safety , Tolerability Activity Study Multiple Doses ISIS-SGLT2Rx Healthy Volunteers</brief_title>
	<detailed_description>To evaluate safety tolerability single subcutaneous injection ISIS-SGLT2Rx administer four increase dose level ( 50 , 100 , 200 , 400 mg ) evaluate safety tolerability multiple dos ISIS 388626 administer subcutaneously either 6 13 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Age 18 65 year Male female gender although female must postmenopausal surgically sterile ( hysterectomy , oophorectomy tubal ligation ) Give write informed consent participate study availability study requirement Fasting plasma glucose &lt; /= upper limit laboratory 's reference range ( ULN ) HbA1c &lt; /= ULN BMI &lt; 30 kg/m² Agree maintain steady hydration throughout study participation agree fluid restrict Pregnant woman , nurse mother woman childbearing potential Clinically significant abnormality medical history physical examination Clinically significant abnormality laboratory examination ( include ALT &gt; ULN , AST &gt; ULN , bilirubin &gt; ULN , creatinine &gt; ULN , urine protein positive urine dipstick , platelet &lt; low limit normal clinically significant laboratory finding ) Estimated GFR &lt; 60 mL/min per 1.73m² History clinically significant abnormality coagulation parameter Positive test result HIV , hepatitis B virus , and/or hepatitis C virus Active infection require antiviral antimicrobial therapy Subjects chronic acute prescription medication may permit discussion Isis Medical Monitor Malignancy ( exception basal squamous cell carcinoma skin adequately treat recurrence &gt; 1 year ) Any concurrent condition , opinion Investigator , would preclude participation study interfere compliance Past present history alcohol drug abuse ( define &gt; 3 unit daily ) Undergoing undergone treatment another investigational drug , biologic agent device within 90 day prior Screening Blood donation within three month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>diabetes</keyword>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>